Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including:

  1. First-in-human study timing
  2. Remaining steps to first-in-human study
  3. Q&A session

Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!

https://youtu.be/NmBiGLHMhFo

  • Message from the CEO: October 2023

    Many of the questions we receive from investors relate to the process for obtaining US Food and Drug Administration (FDA) approval for surgical devices, such as the Ocumetics Accommodating Lens. This month’s message is focused on outlining how the process works and unpacking the steps required to obtain FDA approval. You will be thrilled to

  • Ocumetics Accommodating Lens Technology

    Imagine a world in which glasses and traditional contact lenses become obsolete, and natural vision is restored with a simple and innovative solution.

    That's precisely what we aim to achieve with the Ocumetics Accommodating Lens technology (“Ocumetics Accommodating Lens”).